Pharmsintez company registered in Russia the drug sorafenib under the trade name Flutriksan. The drug suppresses tumor growth in metastatic renal cell, hepatocellular, differentiated thyroid cancer. The company will supply under an exclusive agreement with the Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus. Sorafenib will be available in Russia in early Q3 2022.